# Matrix metalloproteinases as new targets in Alzheimer's disease: Opportunities and Challenges

Article · Pauline Zipfel, Christophe Rochais, Kévin Baranger, Santiago Rivera, Patrick Dallemagne

- Archive id: arxiv:2112.01081
- Published: 2021-12-02
- Venue: Journal of Medicinal Chemistry, American Chemical Society, 2020
- DOI: https://doi.org/10.1021/acs.jmedchem.0c00352
- arXiv: https://arxiv.org/abs/2112.01081
- Citations: 94
- Source URL: https://arxiv.org/abs/2112.01081
- PDF: https://arxiv.org/pdf/2112.01081
- Provenance: arxiv

## Abstract

Although matrix metalloproteinases (MMPs) are implicated in the regulation of numerous physiological processes, evidences of their pathological roles have also been obtained in the last decades, making MMPs attractive therapeutic targets for several diseases. Recent discoveries of their involvement in central nervous system (CNS) disorders, and in particular in Alzheimer's disease (AD), have paved the way to consider MMP modulators as promising therapeutic strategies. Over the past few decades, diverse approaches have been undertaken in the design of

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [Alzheimer's, Parkinson's & Neurodegeneration](https://space-kitty.com/topics/neurodegeneration)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.